Search results
View Ronald Aimes’ profile on LinkedIn, a professional community of 1 billion members. Seeking a scientific or project leadership role in pharmaceutical product…
- 500+
- Mapp Biopharmaceutical Inc
- 892
Jun 11, 2019 · “The award of this contract by BARDA will allow Mapp to advance the development of MBP091 to first in human evaluation with the ultimate goal of making this medical countermeasure available to victims of Marburg virus” said Dr. Ronald Aimes, Vice President of Nonclinical Development at Mapp and the Principal Investigator on this ...
Mar 21, 2024 · "We are pleased to partner with ProBioGen to develop a cell line to produce our afucosylated antibody to treat MARV infection," commented Dr. Ronald Aimes, VP, Development - Marburg at MAPP BIOPHARMACEUTICAL, INC.
Mar 15, 2024 · "We are pleased to partner with ProBioGen to develop a cell line to produce our afucosylated antibody to treat MARV infection," said Ronald Aimes, vice-president, Development—Marburg, Mapp Biopharmaceutical, in the press release.
Ronald Aimes is on Facebook. Join Facebook to connect with Ronald Aimes and others you may know. Facebook gives people the power to share and makes the world more open and connected.
Ronald Aimes. Cloning, expression and characterization of a chicken matrix metalloproteinase and its inhibitor. Ronald Aimes. Appointment Period: 1996-1997 / Grant Year: [11] The cAMP-dependent protein kinase (cAPK) is a serine/threonine kinase that plays a central role in intracellular signaling.
Jul 1, 2019 · Aimes, Ronald T. Mapp Biopharmaceutical, Inc., San Diego, CA, United States. Abstract. Mapp Biopharmaceutical, Inc. (Mapp) is developing antibody-based therapeutics to treat a number of infectious agents, including some of the most dangerous known to man: the filoviruses.
